Physician profile
Mark Shell
NPI 1265097000
$4,205.66
in general payments reported to CMS, 2019-2025
11 companies · $2,390 in 2025
The $2,390 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $122 · 2024: $1,523 · 2025: $2,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,123 · Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,123.12 |
| Food and Beverage | $1,911.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,639.21 | 2022-2025 | Overstitch Endoscopic Suturing System, Axios, General - Therapies |
| Ferring Pharmaceuticals INC. | $156.11 | 2024 | Rebyota |
| Pfizer INC. | $108.35 | 2025 | |
| Abbvie INC. | $102.28 | 2023 | Rinvoq |
| Madrigal Pharmaceuticals | $45.29 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $31.97 | 2024 | Terlivaz |
| Aimmune Therapeutics, INC. | $29.03 | 2025 | Zenpep |
| Apollo Endosurgery US INC | $28.40 | 2022 | |
| Janssen Biotech, INC. | $23.92 | 2025 | Tremfya |
| Enterra Medical, INC. | $20.56 | 2025 | |
| Medtronic, INC. | $20.54 | 2025 | Pillcam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.